Patent classifications
A61P37/06
TRICYCLIC HETEROCYCLES AS ANTICANCER AGENTS
Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following and similar genera:
##STR00001##
in which Het is an aromatic heterocyclic ring and Y is a point of attachment of various side chains and rings. An example of such a compound is 4-chloro-N-(3-(10,11-dihydro-5H-benzo[b]pyrido[2,3-f]azepin-5-yl)propyl)benzenesulfonamide:
##STR00002##
Interferon Alpha and Omega Antibody Antagonists
Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.
IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS
- Laurence Anne Mevellec ,
- Lieven Meerpoel ,
- Sophie Coupa ,
- Virginie Sophie Poncelet ,
- Isabelle Noelle Constance Pilatte ,
- Elisabeth Therese Jeanne Pasquier ,
- Didier Jean-Claude Berthelot ,
- Olivier Alexis Georges Querolle ,
- Christophe Meyer ,
- Patrick Rene Angibaud ,
- Christophe Gabriel Marcel Demestre ,
- Guillaume Jean Maurice Mercey
The present invention relates to substituted imidazopyridazine derivatives of Formula (I)
##STR00001##
wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Cytokine Fusion Proteins
The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
A compound of formula (I′) or (I″) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
##STR00001##
CYCLIC DINUCLEOTIDES USEFUL FOR THE TREATMENT OF INTER ALIA CANCER
A compound of formula (I)
##STR00001##
or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants
Phosphorodiamidate Backbone Linkage for Oligonucleotides
This invention relates to antisense oligonucleotides comprising at least one N3′.fwdarw.P5′ phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression.
SYSTEMS ANDMETHODS TO IMPROVE ORGANOR TISSUE FUNCTION ANDORGANOR TISSUE TRANSPLANT LONGEVITY
The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.
HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
CYCLIC UREAS AS INHIBITORS OF ROCK
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
##STR00001##